LNDC Landec Corp.

Landec Appoints New Chief Financial Officer

Landec Appoints New Chief Financial Officer

SANTA MARIA, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC), a diversified health and wellness company with two operating businesses, Curation Foods, Inc. and Lifecore Biomedical, Inc., today announced the appointment of John D. Morberg as Chief Financial Officer, effective January 18, 2021. Mr. Morberg succeeds Brian McLaughlin, Landec’s current Chief Financial Officer, who has retired. Mr. Morberg will report to Landec’s President and Chief Executive Officer, Dr. Albert Bolles, and will oversee the Company’s finance, legal and investor relations functions.

Dr. Bolles stated, “We are excited to welcome John as our new Chief Financial Officer. He brings tremendous strategic and financial capabilities that we believe will be key as we continue to deliver improvements and advance our growth agenda, and to seek to position the company for resilience and profitability. He is well-aligned with our culture and will be a strong addition to Landec’s executive management team.” Dr. Bolles added, “I would also like to thank Brian McLaughlin for all of his contributions to the company and wish him well in his retirement.”

Mr. Morberg brings over 25 years of corporate finance and executive leadership experience with both public and private companies, including as a CEO, CFO, general counsel and board member. Most recently, he was CFO and General Counsel for BL Restaurant Holdings, LLC, a national restaurant chain. Previously, over a ten-year tenure at Garden Fresh Restaurant Corp, he held various roles, including as the CEO, CFO and board member. He also served as CFO of DEI Holdings, Inc., through its initial public offering and through the early stages of being a public company, and worked for eight-years as Vice President and Controller of PETCO. Mr. Morberg began his career at KPMG.

Mr. Morberg has a Juris Doctor from the University of the Pacific, McGeorge School of Law and a BBA, Accounting from the University of San Diego. He is a member of the State Bar of California and holds a CPA license (inactive).

“I am excited to assume the CFO role at Landec to help the company continue executing its strategic plan, accelerate growth and deliver value to shareholders,” said Mr. Morberg. “I look forward to partnering with the leadership team and the entire company on this journey.”

About Landec Corporation

Landec Corporation (NASDAQ: LNDC) is a leading innovator of diversified health and wellness solutions with two operating businesses: Curation Foods, Inc. and Lifecore Biomedical, Inc. Landec designs, develops, manufactures and sells products for the food and biopharmaceutical industry. Curation Foods is focused on innovating and distributing plant-based foods with 100% clean ingredients to retail, club and foodservice channels throughout North America. Curation Foods is able to maximize product freshness through its geographically dispersed family of growers, refrigerated supply chain and patented BreatheWay® packaging technology. Curation Foods brands include Eat Smart® fresh packaged vegetables and salads, O Olive Oil & Vinegar® premium artisan products and Yucatan® and Cabo Fresh® avocado products. Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 35 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Landec’s website at .

Contact Information:
 
Investor Relations:
Jeff Sonnek
(646) 277-1263

 



EN
19/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Landec Corp.

 PRESS RELEASE

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., July 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on July 11, 2025, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate of 6,338 shares of its common stock and stock options for an aggregate of 29,575 shares of common sto...

 PRESS RELEASE

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Sup...

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer Represents Continuation of Long-Running Partnership Focused on Supporting Advancement of Novel Ophthalmic Therapeutic Toward Commercialization CHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a new 10-year commercial manufacturing and supply agreement with a key existing customer. This represents the latest agreem...

 PRESS RELEASE

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Mill...

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach CHASKA, Minn., June 12, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has received the remaining $10 million in proceeds from the previously disclosed sale of its excess high-speed, multi-purpose 10-head isolator filler. The buyer elected to complete the full paymen...

 PRESS RELEASE

Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer

Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations Will Leverage Deep Pharma Services Expertise as Leader of Lifecore’s Sales Organization Focused on Executing Three-Pronged Growth Strategy CHASKA, Minn., May 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has appointed Mark DaFonsec...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch